Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- recombinant proteins genes regulations epigenetics chromatins research cancers BRD3 expressions histones acetylation bromodomains BRDs BRD2 BRD 2 BRD-2 BRD 3 BRD-3 BRD4 BRD 4 BRD-4 BRDT BRD-T RING3-like H4-K5 H4K-5 H-4K5 4K12 K12 4K14 K14 C2-C12 BRD3NUT
- Product Overview:
Bromodomain-containing protein 3 (BRD3) is a member of the bromodomain and extra-terminal domain (BET) family.{19930} It is composed of two N-terminal bromodomains (BD1 and BD2) that bind acetylated lysine on histones, serving to couple histone acetylation marks to the transcriptional regulation of target promoters, and an extra-terminal domain that mediates chromatin interactions. BRD3 is ubiquitously expressed and localizes to the nucleus where it preferentially binds acetylated histone H4 lysine 5 (H4K5), H4K12, and H4K14 at active transcription sites.{60983,19558} Knockdown of Brd3 enhances differentiation of C2C12 skeletal muscle myoblasts.{60984} Chromosomal translocations leading to the fusion of BRD3 with the nuclear protein in testis (NUT) gene and resulting in expression of BRD3-NUT fusion proteins are associated with NUT midline carcinoma (NMC).{60985} Cayman’s BRD3 bromodomain 2 protein can be used for Western blot (WB).
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.